TABLE 3.
Levels of SV40-neutralizing antibodies and isolation of infectious SV40 from SIV-infected rhesus monkeys
| Animal no. | Value for SV40 serologya
|
SV40 isolation (days to CPE)
|
||||
|---|---|---|---|---|---|---|
| Pre-SIVb | Immunec | Finald | Infection
|
Lipofection
|
||
| Brain filtrate | Brain DNA | PBMCe DNA | ||||
| 6593 | 51,200 | 25,600 | 20,000 | + (≥10) | + (≥12) | + |
| H328 | 12,800 | 25,600 | 40,000 | + (≥10) | + (≥12) | + |
| H388 | 25,600 | NAf | ≥20,000g | + (≥10) | + (≥12) | + |
| H491 | 25,600 | 12,800 | 4,000 | + (≥10) | + (≥12) | 0 |
| H822 | 25,600 | NA | 8,000 | + (≥10) | + (≥12) | NA |
| I508 | 6,400 | 6,400 | 25,600g | + (≥18) | + (≥21) | 0 |
| K661 | <200 | <200 | <200 | + (0.75) | + (≥3) | 0 |
| T302 | NA | NA | NA | + (≥10) | + (≥12) | NA |
a
SV40 neutralizing antibody (reciprocal of highest serum dilution determined to reduce SV40 infectious titer by 50%).
b
SV40 neutralizing antibody prior to infection with SIV (assayed by IHC).
c
SV40 neutralizing antibody 2 or more weeks after infection with SIV (assayed by IHC).
d
SV40 neutralizing antibody at time of death (assayed by plaque reduction, except in two cases).
e
Virus was not recovered from all PBMC samples available for each animal; +, successful virus isolation from at least one PBMC DNA sample; 0, lack of virus isolation from all available PBMC samples.
f
NA, not available.
g
Neutralizing antibody assayed by IHC.